Graves病患者^(131)I治疗前后sIL-2R变化及其临床意义  

The Clinical Significance of Serum Level of Soluble Interleukin-2 Receptor(sIL-2R) in Graves′ Disease Patients before and after Treatment with 131 I

作　　者：张永健[1] 邓力平[1] 丁绚[1] 

机构地区：[1]广州医学院第二附属医院核医学科,广东广州510260

出　　处：《标记免疫分析与临床》2004年第3期138-140,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：探讨格雷夫斯病 (GD)患者13 1I治疗前后免疫功能的变化及其与甲状腺功能的关系。用化学发光法对 2 7例GD患者在13 1I治疗前后分别测定FT3 、FT4、TSH和sIL - 2R ;同时测定 37名对照组的sIL - 2R。GD患者13 1I治疗前组血清sIL - 2R水平为 810± 2 4 8kU/L ,高于治疗后组 (4 5 3± 30 2kU/L)和对照组 (4 10± 130kU/L) ;治疗前组FT3 、FT4与sIL - 2R的相关系数分别为 0 .75 ,0 .5 7,治疗后组FT3 、FT4与sIL - 2R的相关系数分别为0 .71,0 .80。GD患者血清sIL - 2R水平明显升高 ,与FT3 、FT4有良好的相关性 ,经13 1I治疗后 ,患者血清sIL- 2R水平随着甲状腺激素水平的下降而降低。To study the relation between Graves′ disease(GD) and immunity function of GD patients before and after treatment with 131 I, the GD patients were divided into two groups: untreated group, treated group and control group.Level of serum FT 3,FT 4,TSH and sIL-2R were measured in 27 GD patients, and 37 control group by CLIA.Results showed that the serum levels of sIL-2R in untreated group, treated group and control group were 810±248kU/L, 453±302kU/L, 410±130kU/L respectively.In untreated GD patients, the serum levels of sIL-2R were significantly higher than those in the control group and treated group.The levels of sIL-2R in 15 treated patients were significantly decreased.The levels of sIL-2R in two patients group were well correlated with serum FT 3, (r=0.75),FT 4(r=0.57).The level of sIL-2R was also an important factor in patients with GD besides FT 3 and FT 4, it rises along with the FT 3,FT 4; and descends along with them.After therapy with 131 I, the sIL-2R was fall to normal.

关 键 词：格雷夫斯病 受体 白细胞介素-2 甲状腺激素 放射性同位素碘 

分 类 号：R581.1[医药卫生—内分泌]